The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...

This growth is fueled by a surge in startup funding and the introduction of new solutions and services, especially those designed for virtual consultations. Furthermore, integrating artificial ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

The move follows a dramatic breakup in June between Hims & Hers and Danish drug maker Novo Nordisk, which makes the brand name weight loss drug Wegovy. Novo Nordisk accused the Hims & Hers of ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company eyes Canada expansion to offer affordable versions of Novo ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Georgia Tech engineers have created a pill that could effectively deliver insulin and other injectable drugs, making ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...